Pfizer agrees to manufacture Gilead’s coronavirus drug remdesivir
Pfizer has agreed to manufacture and supply Gilead Sciences’ antiviral drug remdesivir, the pharmaceutical giant announced Friday. The multiyear agreement will support efforts to
Tag: SBECD
Breakthrough Therapy Designation Granted for SBECD-enabled Pevonedistat
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its SBECD
European Commission secures EU access to Remdesivir for treatment of COVID-19
The European Commission has signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand
Australia’s TGA approves remdesivir while Gilead reports reduced mortality risk
The Therapeutic Goods Administration (TGA) of Australia has awarded provisional approval for the use of Gilead Sciences’ remdesivir (Veklury) to
Gilead prices remdesivir at 390$/vial for governments
Daniel O’Day, Chairman & CEO, Gilead Sciences posted an open letter yesterday, to share pricing indications for Gilead anti-COVID19 treatment,
Summary of currently available drugs which can be potentially used for treatment of COVID-19
The Table below was published in e-book International Pulmonologist’s Consensus On Covid-19 2nd ed 2020 on April 22nd 2020 (ed. Tinku
Gilead to Initiate Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years
Set-up of an upcoming clinicl trial has been posted with the primary objectives of this study are to evaluate the
A new country to approve remdesivir for COVID-19 treatment: Israel
Israel approved on Tuesday the use of Gilead Sciences Inc’s antiviral drug remdesivir for the treatment of patients with COVID-19
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Eva Pharma, DRL, Biocon and Zydus Cadila added to Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with further generic pharmaceutical manufacturers based in Egypt and India to further expand supply